Mercury Pharmaceuticals business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Mercury Pharmaceuticals is willing to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in cancer biology, translational oncology, and cancer prevention and control studies.
Mercury Pharmaceuticals has a strategic alliance agreement with Aesica Pharmaceuticals to advance the clinical development for the treatment of ovarian cancer and to collaborate on preclinical studies of MP13920 as a treatment for breast cancer based on positive results from a Phase 2 trial of MP13920 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please send us a message.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
29
Mar 2026
People who get just a few minutes of vigorous activity daily are less likely to develop eight major diseases, including arthritis, heart disease and dementia, according to research published in the European Heart Journal today (Monday).
29
Mar 2026
Older patients with coronary artery disease scheduled for transcatheter aortic valve replacement (TAVR) had comparable outcomes regardless of whether they underwent percutaneous coronary intervention (PCI) before TAVR, according to findings from the PRO-TAVI study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
29
Mar 2026
In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within one year, compared with patients who underwent standard repeat mitral valve replacement surgery, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
29
Mar 2026
Researchers found that intestinal tuft cells signal to crypt enterochromaffin cells by releasing acetylcholine, triggering serotonin release and activating a gut-to-brain vagal pathway during type 2 inflammation. This sustained signalling, rather than the initial acute response, was linked to reduced food intake in mouse models of parasitic infection.